MAIA Biotechnology (MAIA) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed XBiotech (XBIT) over the past year, losing 14.1% versus a loss of 14.9%. MAIA Biotechnology is the larger company by market cap ($67.9 million vs $64.6 million), about 1.1 times the size. On valuation, MAIA Biotechnology trades at a lower forward P/E (1.0x vs 16.3x for XBiotech).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | XBIT |
|---|---|---|
| Share price | $1.10 | $2.12 |
| Market cap | $67.92M | $64.63M |
| 1-day change | -1.79% | -1.85% |
| YTD return | -28.10% | -11.30% |
| 1-year return | -14.06% | -14.86% |
| 5-year return | — | -84.94% |
| Forward P/E | 0.99 | 16.31 |
| EPS (TTM) | $-0.62 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.40M | $-45.54M |
| 52-week high | $3.19 | $3.44 |
| 52-week low | $0.87 | $2.09 |
| Distance from 52-week high | -65.52% | -38.37% |
| Analyst consensus | none | — |
| Avg. price target upside | +990.91% | — |
| Average volume | 481.94K | 42.87K |
| Shares outstanding | 61.74M | 30.49M |
| Employees | 13 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
MAIA vs XBIT FAQ
Which is bigger, MAIA Biotechnology or XBiotech?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $67.92M compared with $64.63M for XBiotech (XBIT).
Which stock has performed better over the past year, MAIA or XBIT?
MAIA returned -14.06% over the past 12 months, compared with -14.86% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.